María Jesús Arranz Calderón

16PUBLICATIONS
84CO-AUTHORS
Predictive and prognostic markersChild and adolescent developmentGene expression (incl. microarray and other genome-wide approaches)Cancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 26, 2026
Exploring Dystrophin Expression and Mutations in the DMD and Dystrophin-Glycoprotein Complex Genes as Prognostic Factors in Leiomyosarcomas.

|Dec 31, 2025
VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol.

Juliana Salazar, María J Arranz, Javier Martin-Broto

|Dec 15, 2025
Interplay between motor stereotypies, emotional dysregulation, and sensory reactivity in adolescents and adults with autism spectrum disorder.

María Gema Hurtado Ruíz, María Jesús Arranz Calderón, Víctor Pérez Solá

|Jun 17, 2025
Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments.

Marc Cendrós, Rosa Catalán, Mercè Torra

|Mar 28, 2025
Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 Patients.

Alexandre Serra-Llovich, Natalia Cullell, Olalla Maroñas

|Jan 08, 2025
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.

Juliana Salazar, María J Arranz, Javier Martin-Broto

Pageof 3

Frequent Collaborators

7 joint publications

Juliana Salazar

3 joint publications

Alexandre Serra-LLovich

3 joint publications

Danny Antaki

3 joint publications

Marta Hernandez